RTP Mobile Logo
Meet The Professor: Optimizing the Clinical Management of Hodgkin and Non-Hodgkin Lymphomas — Part 6 of an 8-Part Series (Webinar Audio Proceedings)
Released March 2022

Featuring perspectives from Dr Michael Williams. Published March 17, 2022. (Webinar Audio Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lymphomas.

    LEARNING OBJECTIVES

    • Evaluate patient- and disease-specific factors when designing an optimal induction therapeutic approach for patients with newly diagnosed follicular lymphoma (FL) requiring active therapy.
    • Appreciate the FDA approval of rituximab/lenalidomide for the management of relapsed/refractory (R/R) FL and available Phase III data investigating this combination as front-line therapy, and optimally incorporate this novel approach into treatment algorithms.
    • Assess the FDA-approved indication for polatuzumab vedotin in patients with R/R diffuse large B-cell lymphoma (DLBCL) after at least 2 prior therapies; review emerging first-line data with this agent combined with chemotherapy, and consider how it can be appropriately and safely incorporated into clinical management algorithms.
    • Review the recent FDA approval of loncastuximab tesirine for patients with R/R large B-cell lymphoma after 2 or more lines of systemic therapy, and consider how this agent can be appropriately and safely incorporated into clinical management algorithms.
    • Understand the mechanism of action of tafasitamab, and appreciate research data documenting the efficacy and safety of this novel, FDA-approved anti-CD19 antibody in combination with lenalidomide for patients with R/R DLBCL.
    • Review available efficacy and safety data with chimeric antigen receptor T-cell therapies directed at CD19, and identify patients with non-Hodgkin lymphoma for whom this approach may be appropriate as part of or outside a clinical research study.
    • Consider clinical, biologic and patient-related factors in the selection and sequencing of therapies for patients with classical Hodgkin lymphoma.
    • Consider patient age, performance status and other clinical and biologic factors in the selection of up-front and subsequent treatment for mantle cell lymphoma.
    • Recall the design of ongoing clinical trials evaluating other novel investigational strategies for the treatment of Hodgkin and non-Hodgkin lymphomas, and counsel appropriately selected patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPLymphoma21/Part6/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/MTPLymphoma21/Part6/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPLymphoma21/Part6/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/MTPLymphoma21/Part6.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Michael E Williams, MD, ScM
    Byrd S Leavell Professor of Medicine
    Chief, Hematology/Oncology Division
    Physician Lead, Cancer Service Line
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee: AbbVie Inc, Celgene Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Kymera Therapeutics, TG Therapeutics Inc; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Novartis and Seagen Inc.

    Release date: March 2022
    Expiration date: March 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):